Biomarkers Consortium Launches Adaptive Trial To Test Targeted Breast Cancer Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The newly launched I-SPY 2 trial will put into practice many ideas about adaptive trial design and the use of biomarkers for patient selection, and it could herald the coming of a new model of drug development.
You may also be interested in...
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.
Beyond The Guidance: The Business Of Co-Development Combinations
FDA put together its well-received draft guidance on co-development of experimental drugs to be used in combination in less than a year, but even with regulators on board and the science burgeoning, the timeline for finding predictable ways for companies to actually collaborate on combining investigative cancer therapies looks to be much longer.